News and Trends 8 Nov 2022 MedinCell’s partner AIC registers trial for drug for total knee replacement pain A partner of MedinCell, Arthritis Innovation Corporation (AIC), has registered a phase 3 trial to look into an alternative drug to deal with pain after total knee replacement (TKR). Arthritis Innovation Corporation conducts and finances all development activities of the drug F14, or mdc-CWM, being trialed. It was registered with the safety and efficacy study […] November 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Rallybio announces positive phase 1 results for drug treating PNH and gMG Affibody’s licensee Rallybio Corporation has announced positive topline results from a phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 7 Nov 2022 AI could tackle pharmaceutical manufacturing bottlenecks Artificial intelligence (AI) is making waves in the world of drug discovery. Rajiv Anand, founder and CEO of the firm Quartic.ai, explains how the tool could also make pharmaceutical manufacturing more efficient. The use of AI in drug discovery is attracting big investor interest; around $1.4 billion so far this year has gone to startups […] November 7, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 7 Nov 2022 Sensorion granted rare pediatric disease designation by FDA for lead therapy gene Sensorion has announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation to its lead therapy gene candidate, OTOF-GT. The gene therapy is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion’s OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one […] November 7, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 TMRW Life Sciences FDA-approved tech will help more people start families Fertility technology company, TMRW Life Sciences Inc., has received FDA clearance for its latest technology that will help more people build families. The CryoRobot Select marks the latest milestone in the company’s expansion of its technology-enabled portfolio. USA-based TMRW says advances like theirs in assisted reproductive technology are helping people start families when they otherwise […] November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation This week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation’s CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution […] November 4, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Companies with exclusive rights to CRISPR diagnostic methods sign agreement Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S. and Greater China have signed a licensing agreement. Sherlock Biosciences announced today (November 3) that it has signed a deal with China-based Tolo Biotech which grants co-exclusive rights to the Cas12 and Cas13 method patents. As the only two companies […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Trial and new drug for Tourette Syndrome after $250M after funding round completed A phase 3 clinical trial and the potential commercialization of a new class of drug for patients with Tourette Syndrome have been funded after an upsized and oversubscribed $250 million series D funding round. Emalex Biosciences announced the closing today (November 3) of the round that was led by Bain Capital Life Sciences with participation […] November 3, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Positive results of cancer treatment to be presented at Boston conference Results of a cancer treatment in the treatment of gynecologic and breast cancer are to be presented next week, November 8-12, at the Society for Immunotherapy of Cancer (SITC) conference in Boston. Alderaan Biotechnology is a preclinical biotech company that focuses on monoclonal antibody development. It will be making announcements about the most recent development […] November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 VectorBuilder to build gene delivery campus after $57M funding Gene delivery technology company VectorBuilder Inc. has announced the completion of $57 million in funding. The funding, co-led by Legend Capital, will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. VectorBuilder was established in 2014 to commercialize its novel e-commerce […] November 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Alkermes to separate oncology business Alkermes plc is to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, its board and external financial and legal advisors plan to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business. Alkermes said […] November 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Avista Capital Partners acquires Taconic Biosciences Private equity company Avista Capital Partners has acquired Taconic Biosciences, a provider of genetically engineered research models (GEMs) and related services, from H.I.G. Capital. Transaction terms were not disclosed. Founded in 1952 and headquartered in Rensselaer, N.Y., Taconic Biosciences specializes in genetically engineered research models and services, specifically murine models for use in drug discovery […] November 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email